The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Image by Arek Socha from Pixabay November 12, 2024 - By Lorna Fernandes - As fall arrives, so does respiratory syncytial ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

The FDA has endorsed Pfizer’s respiratory ... While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to determine how ...

In June, the FDA expanded the approval of GSK's RSV vaccine (Arexvy) to include adults ages 50-59 at increased risk of lower ...

The FDA has approved Pfizer’s respiratory syncytial ... for severe RSV should receive a single dose of the RSV vaccine (Arexvy [GSK], Abrysvo [Pfizer], or mResvia [Moderna]).

This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...

Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults aged over 18 years.

GSK is also conducting clinical studies on Arexvy for expanded use in adults aged 18-49 years. Moderna MRNA secured FDA approval for its mRNA-based RSV vaccine, mResvia, this May to prevent RSV ...

Pfizer's Abrysvo is FDA-approved to prevent RSV in adults 18-59 ... with 65% opting for GSK's Arexvy. However, this September, the weekly average fell to 157,000. Price Action: PFE stock is ...

Other companies also have FDA-approved RSV vaccines , including Moderna’s mResvia and GSK’s Arexvy. However, Pfizer’s Abrysvo ...